

ABSOLUTE STRUCTURE OF (+)-13 $\beta$ -HYDROXYMAMANINE,  
A POSSIBLE METABOLITE OF (-)-BAPTIFOLINE

Hajime KUBO,\*<sup>a</sup> Shigeru OHMIYA,<sup>a</sup> Kimio HIGASHIYAMA,<sup>a</sup> Ken-ichi KAWAI,<sup>a</sup>  
Kazuki SAITO,<sup>b</sup> and Isamu MURAKOSHI<sup>b</sup>

Faculty of Pharmaceutical Sciences, Hoshi University,<sup>a</sup>

Ebara 2-4-41, Shinagawa-ku, Tokyo 142, Japan and

Faculty of Pharmaceutical Sciences, Chiba University,<sup>b</sup>

Yayoi-cho 1-33, Inage-ku, Chiba 260, Japan

The absolute structure of (+)-13 $\beta$ -hydroxymamanine (**1**), isolated from an alkaloidal component of *Maackia amurensis* (Leguminosae), has been established as (7*R*, 9*S*, 11*R*, 13*R*) by the X-ray analysis of its hydrobromide. The absolute stereochemistry of **1** is the same as that of the structure corresponding to an oxidative product derived from (-)-baptifoline (7*R*, 9*R*, 11*R*, 13*R*) coexisting in the same plant. It was strongly suggested that **1** might be an oxidative metabolite of (-)-baptifoline.

**KEYWORDS** lupin alkaloid; quinolizidine alkaloid; *Maackia amurensis*; absolute configuration; X-ray analysis; (+)-13 $\beta$ -hydroxymamanine

As a result of screening plants belonging to the Genus *Maackia* (Leguminosae) for lupin alkaloid,<sup>1,2</sup> (+)-13 $\beta$ -hydroxymamanine (**1**) was isolated from the aerial parts of *Maackia amurensis* as a colorless crystal [ $\alpha$ ]<sub>D</sub>+31.2 (*c*=0.107, MeOH), together with (-)-cytisine, (-)-anagyrene, (-)-*N*-methylcytisine, (-)-lupanine, (-)-baptifoline, *N*-formylcytisine, ammodendrine, and camoensidine. Its structure has been proposed to be **1** or its enantiomer from spectroscopic data.<sup>3</sup>

(+)-13 $\beta$ -Hydroxymamanine (**1**) can be structurally correlated with the unusual lupin alkaloids (+)-mamanine (**2**),<sup>4</sup> (-)-pohakuline (**3**),<sup>4</sup> and (+)-kuraramine (**4**)<sup>5</sup> (Fig. 1).




Fig. 1

The structures of **1-4** correspond to oxidative products derived from the N1-C10 bond cleavage of the usual tetra and tricyclic lupin alkaloids (-)-baptifoline (**5**), (-)-anagyrene (**6**), (-)-lupanine (**7**), and (-)-*N*-methylcytisine (**8**), respectively (Fig. 2).




Fig. 2

The factoring of absolute configuration into the structural relationship between the unbridged alkaloids (1-4) and the bridged alkaloids (5-8) is of interest in connection with their biosynthetic correlations. However, absolute configurations of the unbridged alkaloids (1-4) have not been determined because they were minor components in the plants, though those of the bridged alkaloids (5-8) are known.

In order to confirm the structure of 1, an X-ray structure analysis of 1 hydrobromide hydrate was undertaken. Crystals of 1 hydrobromide hydrate (mp 168°C) suitable for X-ray analysis were grown by the slow evaporation of ethanol containing 1%-H<sub>2</sub>O. The molecular structure of 1 hydrobromide hydrate is illustrated in Fig. 3. Thus absolute configuration of (+)-13β-hydroxymamanine (1) (7*R*, 9*S*, 11*R*, 13*R*) was confirmed by heavy-atom anomalous dispersion of its hydrobromide hydrate.




Fig. 3

The absolute configuration of **1** is the same as that of the oxidative product derived from (-)-baptifoline(**5**), coexisting in the same plant. The absolute configurations of the other unbridged alkaloids(**2-4**) are expected to be the same as that of (-)-anagryrine (**6**; *7R*, *9R*, *11R*), (-)-lupanine (**7**; *6S*, *7R*, *9R*, *11R*), and (-)-*N*-methylcytisine (**8**; *7R*, *9S*), respectively.

From the stereochemical point of view among the lupin alkaloids, it can therefore be presumed that (+)-13 $\beta$ -hydroxymamanine is a metabolite of (-)-baptifoline. From the same standpoint, (+)-mamanine (**2**), (-)-pohakuline (**3**), and (+)-kuraramine (**4**) are suggested to be metabolites of (-)-anagryrine (**6**), (-)-lupanine (**7**), and (-)-*N*-methylcytisine (**8**), respectively.

### X-Ray Structure Analysis

Crystal Data: C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> HBr H<sub>2</sub>O (mp 168°C); *M*=377.28; monoclinic; *P*2<sub>1</sub>(#4); *a*=10.901(3), *b*=7.440(3), *c*=11.232(3) Å,  $\beta$ =114.10(2)°; *V*=835.0(4) Å<sup>3</sup>; *Z*= 2; *D*<sub>c</sub>=1.501 g/cm<sup>3</sup>; *F*(000)=392.00.

The diffraction intensities were collected from a (+)-13 $\beta$ -hydroxymamanine hydrobromide hydrate with a crystal with dimensions of 0.20 × 0.20 × 0.30mm on a Rigaku AFC7R diffractometer with graphite monochromated Cu-K $\alpha$  radiation ( $\lambda$ =1.54178Å). A total of 2868 reflections were measured within a  $2\theta$  range of 120° as above the 3.00 $\sigma$ (*I*) level. These were used in the solution and refinement of the structure.

Determination of the structure: The structure was resolved by direct methods using SAPI91<sup>6)</sup> and refined by the full-matrix least-squares method.

In the final refinement, anisotropic thermal parameters were used for non-hydrogen atoms. The contribution of hydrogen atoms of hydrate was ignored. The final *R* factor was 0.040.<sup>7)</sup>

### REFERENCES AND NOTES

- 1) K. Saito, T. Yoshino, S. Tsai, S. Ohmiya, H. Kubo, H. Otomasu, I. Murakoshi, *Chem. Pharm. Bull.*, **35**, 1308 (1987).
- 2) S. Ohmiya, H. Kubo, H. Otomasu, K. Saito, I. Murakoshi, *Heterocycles*, **30**, 537 (1990).
- 3) K. Saito, S. Tsai, S. Ohmiya, H. Kubo, H. Otomasu, I. Murakoshi, *Chem. Pharm. Bull.*, **34**, 3982 (1986).
- 4) M. M. Kadooka, M. Y. Chang, H. Fukami, P. J. Scheuer, J. Clardy, B. A. Solheim, J. P. Springer, *Tetrahedron*, **32**, 919 (1976).
- 5) I. Murakoshi, E. Kidoguchi, J. Haginiwa, S. Ohmiya, K. Higashiyama, H. Otomasu, *Phytochemistry*, **20**, 1407 (1981).
- 6) SAPI91: H. F. Fan (1991). Structure Analysis Programs with Intelligent Control, Rigaku Corporation, Tokyo, Japan.
- 7) Lists of *F*<sub>o</sub> and *F*<sub>c</sub> values, tables of final atomic parameters, bond length and angles, anisotropic thermal parameters, and atomic fractional parameters are available from one of the authors(H.K.) upon request.

(Received June 6, 1994; accepted June 29, 1994)